HighMark Wealth Management’s Definium Therapeutics DFTX Stock Holding History

HighMark Wealth Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.35K	Sell	50 -50	-50%	-$1.24K	﹤0.01%	454
2026 Q1	$1.89K	Hold	100	–	–	﹤0.01%	464
2025 Q4	$1.34K	Hold	100	–	–	﹤0.01%	500
2025 Q3	$1.18K	Hold	100	–	–	﹤0.01%	522
2025 Q2	$649	Hold	100	–	–	﹤0.01%	547
2025 Q1	$585	Hold	100	–	–	﹤0.01%	519
2024 Q4	$696	Buy	100 +22	+28%	+$151	﹤0.01%	513
2024 Q3	$444	Hold	78	–	–	﹤0.01%	549
2024 Q2	$562	Buy	78 +50	+179%	+$437	﹤0.01%	531
2024 Q1	$263	Hold	28	–	–	﹤0.01%	546
2023 Q4	$102	Hold	28	–	–	﹤0.01%	566
2023 Q3	$88	Sell	28 -1	-3%	-$4	﹤0.01%	558
2023 Q2	$104	Hold	29	–	–	﹤0.01%	551
2023 Q1	$92	Sell	29 -26	-47%	-$86	﹤0.01%	594
2022 Q4	$121	Sell	55 -59	-52%	-$164	﹤0.01%	525
2022 Q3	$0	Sell	114 -31	-21%	-$298	﹤0.01%	544
2022 Q2	$1K	Buy	145 +11	+8%	+$139	﹤0.01%	481
2022 Q1	$2K	Buy	+134	New	+$2.33K	﹤0.01%	449

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HighMark Wealth Management's DFTX Position: Q2 2026 in Review

HighMark Wealth Management reduced its Definium Therapeutics (DFTX) stake by 50% in Q2 2026, selling an estimated $1.24K and leaving 50 shares worth $2.35K. The position accounts for ﹤0.01% of the portfolio, ranked #454.

HighMark Wealth Management first reported a position in DFTX in Q1 2022 and has held it in 18 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

HighMark Wealth Management held 50 shares of Definium Therapeutics worth $2.35K as of Q2 2026.
HighMark Wealth Management sold 50 Definium Therapeutics shares in Q2 2026, an estimated $1.24K.
Definium Therapeutics made up ﹤0.01% of HighMark Wealth Management's portfolio in Q2 2026, its #454 holding.
HighMark Wealth Management first reported a position in Definium Therapeutics in Q1 2022 and has held it in 18 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.